arrow
S

Scott C. Morgan

the ottawa hospital cancer centre
H指数:26
被引数:4,019

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Differential Association of Post–Testosterone Recovery PSA Kinetics with Progression and Metastatic Outcomes in Non-metastatic Prostate Cancer

非转移性前列腺癌中,雄激素剥夺治疗后睾酮恢复时PSA动力学与进展和转移结局的差异性关联

2026-09-280
PRE
Association of race and survival in patients treated with apalutamide: Pooled analysis of two phase 3 trials

种族与接受阿帕鲁他胺治疗患者生存期的关联:两项III期试验的合并分析

Cancer
IF5.1
2026-01-010
PRE
Early favorable prostate-specific antigen response prediction in metastatic hormone sensitive prostate cancer

早期对转移性激素敏感型前列腺癌的 prostate-specific antigen (PSA) 阳性反应预测

2025-12-170
OAAI
Assessing Quality and Adherence to PI-RADSv2.1 Minimum Technical Standards of Prostate MRI in NRG-GU005

评估前列腺MRI的质量和符合PI-RADSv2.1最低技术标准的情况:NRG-GU005研究

2025-10-080
OAAI
Association of patient and physician characteristics with androgen-deprivation-therapy intensification in patients with de novo hormone-sensitive metastatic prostate cancer: A population-based study

患者和医师特征与雄激素剥夺疗法强化治疗在去势敏感型转移性前列腺癌初诊患者中的关联:一项基于人群的研究

Cancer
IF5.1
2025-09-040
OAAI
Efficacy of Stereotactic Ablative Body Radiotherapy (SABR) in uncommon subtypes of primary kidney cancer: An analysis from the International Radiosurgery Oncology Consortium of the Kidney

立体定向消融体部放射治疗(SABR)在不常见类型原发性肾癌中的疗效:国际肾脏放射外科肿瘤学协作组(International Radiosurgery Oncology Consortium of the Kidney)的分析

2025-09-020
PRE
Phase III trial of dose escalated radiation therapy and standard androgen deprivation therapy (ADT) vs. dose escalated radiation therapy and enhanced ADT with orteronel for men with high-risk prostate cancer (NRG/RTOG 1115)

剂量 escalated 放射治疗和标准雄激素剥夺治疗(ADT)与剂量 escalated 放射治疗和奥曲酮增强雄激素剥夺治疗的高危前列腺癌患者的III期试验(NRG/RTOG 1115)

2025-07-230
PRE
Radiotherapy- Versus Surgery-based Treatment Strategy in High-risk Prostate Cancer

放疗与手术为基础的治疗策略在高风险前列腺癌中的比较

2025-07-190
PRE
A single institution retrospective study of pelvic insufficiency fractures following curative-intent pelvic intensity-modulated radiation therapy for gynecologic, gastrointestinal, and genitourinary cancers

一项单机构回顾性研究,探讨妇科、胃肠道和泌尿生殖系统癌患者在接受根治性盆腔调强放射治疗后发生的盆腔不全骨折。

2025-04-020
PRE
Testosterone Recovery Following Androgen Suppression and Prostate Radiotherapy (TRANSPORT): A Pooled Analysis of Five Randomized Trials from the Meta-Analysis of Randomized Trials in Cancer of the Prostate (MARCAP) Consortium

雄激素抑制和前列腺放疗后的睾酮恢复 (TRANSPORT): 来自前列腺癌随机试验荟萃分析 (MARCAP) 联盟的五个随机试验的汇总分析

2025-01-011
PRE
Long-term Renal Function Outcomes After Stereotactic Ablative Body Radiotherapy for Primary Renal Cell Carcinoma Including Patients with a Solitary Kidney: A Report from the International Radiosurgery Oncology Consortium of the Kidney

包括孤立肾患者在内的原发性肾细胞癌立体定向消融放疗后的长期肾功能预后: 国际肾脏放射外科肿瘤学联合会的报告

2024-12-013
PRE
Metabolic, cardiac, and bone health testing in patients with prostate cancer on androgen-deprivation therapy: A population-based assessment of adherence to therapeutic monitoring guidelines
CANCER
IF5.1
2024-10-130
OAAI
Early Prostate-Specific Antigen Response by 6 Months Is Predictive of Treatment Effect in Metastatic Hormone Sensitive Prostate Cancer: An Exploratory Analysis of the TITAN Trial
2024-07-261
PRE
Effect of Prior Prostate Directed Local Therapy on Response to Apalutamide in Metastatic Hormone Sensitive Prostate Cancer: A Secondary Analysis of the TITAN Study
2024-04-011
PRE